Fecha de publicación: 17/01/2025 Fuente: FierceBiotech One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for post-traumatic stress disorder. But the biotech has reminded us this week that it hasn’t given up hope yet.